Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.59 |
| ▸ | ALK | Q9UM73 | 12/20 | 0.55 |
| ▸ | ROS1 | P08922 | 5/20 | 0.55 |
| ▸ | EGFR | P00533 | 3/20 | 0.55 |
| ▸ | CDK7 | P50613 | 1/20 | 0.55 |
| ▸ | CDK9 | P50750 | 1/20 | 0.55 |
| ▸ | INSR | P06213 | 6/20 | 0.54 |
| ▸ | IGF1R | P08069 | 2/20 | 0.54 |
| ▸ | MET | P08581 | 2/20 | 0.52 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12826706 | 0.89 | EGFR (0.55) | LRRK2ALKEGFRINSRMAPK3 | |
| SCHEMBL12826442 | 0.89 | IGF1R (0.53) | LRRK2ALKROS1EGFRIGF1R | |
| SCHEMBL16995451 | 0.86 | LRRK2 (0.69) | LRRK2ALKINSRMAPK3 | |
| SCHEMBL12826742 | 0.86 | LRRK2 (0.65) | LRRK2 | |
| SCHEMBL12826443 | 0.85 | LRRK2 (0.70) | LRRK2ALKINSRMAPK3 | |
| SCHEMBL12826701 | 0.83 | LRRK2 (0.60) | LRRK2ALKINSRMAPK3 | |
| SCHEMBL13191141 | 0.83 | ALK (0.58) | LRRK2ALKROS1EGFRCDK7 | |
| SCHEMBL13191368 | 0.83 | LRRK2 (0.67) | LRRK2ALKEGFRCDK7CDK9 | |
| SCHEMBL12826576 | 0.82 | LRRK2 (0.61) | LRRK2IGF1R | |
| SCHEMBL16995435 | 0.81 | PTK2 (0.68) | LRRK2ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2408752-B1 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2015-08-12 | — | — | EP | disclosed |
| US-20140051674-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-20 | — | — | US | disclosed |
| US-20140051674-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-20 | — | — | US | disclosed |
| US-20110071158-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-24 | — | — | US | disclosed |
| US-20110071158-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051674-A1 | NEW COMPOUNDS | CCNA1, MKI67, CCNT1 | LRRK2 1540/4885ALK 2070/4885ROS1 329/4885 |
| US-20110071158-A1 | NEW COMPOUNDS | CCNA1, MKI67, CCNT1 | LRRK2 1540/4885ALK 2070/4885ROS1 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.